Peptide Ligands Specifically Targeting HER2 Receptor and the Role Played by a Synthetic Model System of the Receptor Extracellular Domain: Hypothesized Future Perspectives

• Published in: Journal of medicinal chemistry 2020-12, Vol.63 (24), p.15333-15343
• Main Authors: Luca, Stefania De, Verdoliva, Valentina, Saviano, Michele
• Format: Article
• Language: English
• Subjects: Animals; Binding Sites; Humans; Immunoconjugates - chemistry; Immunoconjugates - metabolism; Isotope Labeling; Ligands; Magnetic Resonance Imaging; Molecular Dynamics Simulation; Neoplasms - diagnostic imaging; Neoplasms - metabolism; Neoplasms - pathology; Pentetic Acid - chemistry; Peptides - chemistry; Peptides - metabolism; Protein Binding; Receptor, ErbB-2 - agonists; Receptor, ErbB-2 - antagonists & inhibitors; Receptor, ErbB-2 - metabolism; Tissue Distribution; Trastuzumab - chemistry
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/acs.jmedchem.0c01340

A short (Fab)­trastuzumab-derived peptide specific for HER2 receptor was identified. Its affinity for the model system HER2-DIVMP was found in a nanomolar range. The structural determinants responsible for the interaction between this ligand (A9) and HER2-DIVMP were investigated by both computational and NMR analysis. Next, the possibility of using A9 as HER2- specific probe for the nuclear medicine imaging was evaluated by conjugating A9 with the DTPA chelator and radiolabeling it with 111In. The developed probe retained a nanomolar affinity to HER2-overexpressing cancer cells, however, some unspecific binding also occurred. The peptide internalization into cells by receptor-mediated endocytosis was also studied. Future perspectives are aimed at using A9 as a probe for molecular imaging diagnostics as well as active targeting of anticancer drugs. Lead structure optimization is needed to minimize the percentage of A9 unspecific binding and to increase the binding affinity to the receptor.